Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial

BACKGROUND: Platinum/fluoropyrimidine regimens are the backbone of first-line chemotherapy for advanced gastric cancer (AGC). However response rates to first line chemotherapy range from 30 to 50% and disease progression occurs after 4–6 cycles. The optimal duration of first-line therapy is still un...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC Cancer
Hauptverfasser: Di Bartolomeo, Maria, Niger, Monica, Morano, Federica, Corallo, Salvatore, Antista, Maria, Tamberi, Stefano, Lonardi, Sara, Di Donato, Samantha, Berardi, Rossana, Scartozzi, Mario, Cardellino, Giovanni Gerardo, Di Costanzo, Francesco, Rimassa, Lorenza, Luporini, Alberto Gianluigi, Longarini, Raffaella, Zaniboni, Alberto, Bertolini, Alessandro, Tomasello, Gianluca, Pinotti, Graziella, Scagliotti, Giorgio, Tortora, Giampaolo, Bonetti, Andrea, Spallanzani, Andrea, Frassineti, Giovanni Luca, Tassinari, Davide, Giuliani, Francesco, Cinieri, Saverio, Maiello, Evaristo, Verusio, Claudio, Bracarda, Sergio, Catalano, Vincenzo, Basso, Michele, Ciuffreda, Libero, De Vita, Ferdinando, Parra, Hector Soto, Fornaro, Lorenzo, Caporale, Marta, de Braud, Filippo, Pietrantonio, Filippo
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2019
Schlagworte:
Study Protocol
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6440108/
https://ncbi.nlm.nih.gov/pubmed/30922323
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5498-3
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge